Daiichi Sankyo
Sarah Spang has extensive experience in the oncology and pharmaceutical sectors, currently serving as Associate Director, Central Regional Marketing Liaison for Oncology Breast at Daiichi Sankyo US since January 2019. Prior roles at Daiichi Sankyo include Associate Director of Oncology Account Management and Regional Oncology Account Manager. Before joining Daiichi Sankyo, Sarah held the position of Area Business Manager at Sanofi Genzyme from January 2017 to January 2019, and worked at Amgen from August 2009 to January 2017, specializing in oncology account management. Earlier career experience includes a role as Specialty Senior Sales Professional in Urology at sanofi-aventis from July 2000 to August 2009, where responsibilities included direct sales of injectable therapies for advanced prostate cancer. Sarah Spang's educational background includes a Bachelor of Arts degree in Secondary Education and Teaching, with a focus on Biology and General Science from Marshall University.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.